See more : Alps Alpine Co., Ltd. (6770.T) Income Statement Analysis – Financial Results
Complete financial analysis of Avantor, Inc. (AVTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avantor, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Sat Industries Limited (SATINDLTD.NS) Income Statement Analysis – Financial Results
- BioPlus Acquisition Corp. (BIOSW) Income Statement Analysis – Financial Results
- RightCrowd Limited (RCWDF) Income Statement Analysis – Financial Results
- Daifuku Co., Ltd. (DAIUF) Income Statement Analysis – Financial Results
- Xvivo Perfusion AB (publ) (XVIPY) Income Statement Analysis – Financial Results
Avantor, Inc. (AVTR)
About Avantor, Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.97B | 7.51B | 7.39B | 6.39B | 6.04B | 5.86B | 1.25B | 691.30M | 636.90M | 4.91B |
| Cost of Revenue | 4.60B | 4.91B | 4.88B | 4.31B | 4.12B | 4.04B | 814.60M | 371.60M | 374.70M | 2.31B |
| Gross Profit | 2.36B | 2.60B | 2.50B | 2.08B | 1.92B | 1.82B | 432.80M | 319.70M | 262.20M | 2.60B |
| Gross Profit Ratio | 33.93% | 34.65% | 33.88% | 32.54% | 31.80% | 31.03% | 34.70% | 46.25% | 41.17% | 53.01% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.10M | 21.90M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.51B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.60M | 1.47B |
| Other Expenses | 0.00 | -800.00K | 10.60M | 9.90M | 2.50M | 3.00M | 3.40M | 200.00K | -300.00K | 0.00 |
| Operating Expenses | 1.66B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.90M | 1.47B |
| Cost & Expenses | 6.26B | 6.38B | 6.41B | 5.69B | 5.49B | 5.45B | 1.46B | 681.40M | 576.60M | 3.78B |
| Interest Income | 0.00 | 265.80M | 229.30M | 307.60M | 440.00M | 0.00 | 0.00 | 0.00 | 30.60M | 0.00 |
| Interest Expense | 284.80M | 265.80M | 217.40M | 307.60M | 440.00M | 523.80M | 200.90M | 80.30M | 0.00 | -265.80M |
| Depreciation & Amortization | 402.30M | 405.50M | 379.20M | 395.40M | 398.90M | 404.60M | 99.20M | 60.30M | 60.70M | 0.00 |
| EBITDA | 1.13B | 1.53B | 1.35B | 765.30M | 879.50M | 814.60M | -91.20M | 70.40M | 121.10M | 1.13B |
| EBITDA Ratio | 16.19% | 20.43% | 18.44% | 17.39% | 15.78% | 14.00% | -8.64% | 10.18% | 19.00% | 23.02% |
| Operating Income | 696.40M | 1.13B | 972.20M | 706.80M | 551.80M | 413.50M | -210.40M | 9.90M | 60.30M | 1.13B |
| Operating Income Ratio | 10.00% | 15.04% | 13.16% | 11.05% | 9.14% | 7.05% | -16.87% | 1.43% | 9.47% | 23.02% |
| Total Other Income/Expenses | -285.90M | -279.10M | -219.20M | -644.50M | -511.20M | -527.30M | -249.80M | -80.50M | -30.50M | -279.10M |
| Income Before Tax | 410.50M | 851.10M | 753.00M | 62.30M | 40.60M | -113.80M | -460.20M | -70.60M | 29.80M | 851.10M |
| Income Before Tax Ratio | 5.89% | 11.33% | 10.19% | 0.97% | 0.67% | -1.94% | -36.89% | -10.21% | 4.68% | 17.34% |
| Income Tax Expense | 89.40M | 164.60M | 180.40M | -54.30M | 2.80M | -26.90M | -314.90M | 10.10M | 17.10M | -164.60M |
| Net Income | 321.10M | 686.50M | 572.60M | 116.60M | 37.80M | -86.90M | -112.70M | -42.40M | 21.60M | 686.50M |
| Net Income Ratio | 4.61% | 9.14% | 7.75% | 1.82% | 0.63% | -1.48% | -9.03% | -6.13% | 3.39% | 13.98% |
| EPS | 0.48 | 1.02 | 0.86 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.05 |
| EPS Diluted | 0.47 | 1.01 | 0.85 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.01 |
| Weighted Avg Shares Out | 675.60M | 650.90M | 590.50M | 576.30M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 650.90M |
| Weighted Avg Shares Out (Dil) | 678.40M | 679.40M | 599.60M | 583.40M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 679.40M |
MD or AVTR: Which Is the Better Value Stock Right Now?
Avantor® to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Avantor to Distribute Quantum-Si's Next-Generation Protein Sequencing™ Technology
Avantor® Opens New Bridgewater Innovation Center Focused on Solving Life Science's Biggest Challenges
MD vs. AVTR: Which Stock Is the Better Value Option?
Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors
Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down
Avantor Inc. (AVTR) Q3 2024 Earnings Call Transcript
Avantor (AVTR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Avantor, Inc. (AVTR) Beats Q3 Earnings Estimates
Source: https://incomestatements.info
Category: Stock Reports